Genentech
DNA
Performance
About Genentech
Genentech is a leading biotechnology company focused on discovering, developing, and delivering medicines for patients in areas including oncology, neuroscience, and ophthalmology. The company emphasizes breakthrough science and patient-focused support, with programs for enrollment, insurance understanding, and disease education. Based in the United States, Genentech operates as a research-driven biopharmaceutical organization committed to advancing therapies through clinical trials and collaboration with medical professionals and patient communities.
Recent News
Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Burnout Common but Regrets Are Not in Allergy, Immunology
Roche Raises NC Manufacturing Investment to $2B To Support Obesity Challenge
Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL
AI Pioneers Unite to Launch the Shared AI License Foundation to Advance Foundation Model Innovation
Why Owning the Learning Loop Matters More Than Owning the Lab
JPM Recap; Mirador Raises $250M; Genentech’s PBM Shift; and More
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
Seven Biotech Companies to Know in the Netherlands
Gene Therapy Reduces Geographic Atrophy Lesion Growth
Storm Therapeutics Secures $56M to Advance Cancer Drugs
Parkinson’s Awareness Month and World Parkinson’s Day 2026: Advocacy and Therapeutic Progress
Fenebrutinib (GDC-0853)
Combination of Ranibizumab, Dexamethasone Superior to Ranibizumab Alone for Macular Edema
Roche Boosts NC Factory Investment to $2B; Rentschler CEO Steps Down
Gut Microbe May Be Linked to Lupus Pathogenesis
Teva Intensifies Biosimilar Competition with FDA Approval and Dual Filing Acceptance in US and Europe
GSK Reaches $2.2bn Deal to Buy Food Allergy Biotech RAPT
Genentech CEO Says Pharmacy Benefit Manager Shift Will Save $70M
Genentech, SanegeneBio Launch Up-to-$1.7B RNAi Collaboration
Once More Into the Valley of Death: Navigating SBIR/STTR Funding for Tech Startups After 2025
JPM Lineup: New Roles Across Industry
JPM 2026: What’s the Outlook Like This Year?
Tozorakimab Scores Double Win in Phase III COPD Trials
StockWatch: IPO Market Shows Sign of Life with Avalyn Filing
What Sanofi’s Multiple Sclerosis Troubles Could Mean for the Space
STAT+: Pharmalittle: We’re Reading About FDA Backing Domestic Production, Another Gilead Deal, and More
ArkBio Starts First‑Cohort Dosing of Long‑Acting Antiviral AK0406 in Australian Phase I Trial
Benefits of a Virtual Asthma Self-Management Education Program
Recent Deals
No recent deals for this company.
